Abstract
Immuno-oncology (IO) therapy has improved outcomes for patients with advanced non-small cell lung cancer (NSCLC) versus chemotherapy in clinical trials. In Germany, immune checkpoint inhibitors have been used clinically since 2015 for patients with advanced/metastatic NSCLC without ALK/EGFR aberrations. As part of I-O Optimise, a multinational research program utilizing real-world data on thoracic malignancies, we describe the evolution of treatment patterns and overall survival (OS) for patients with advanced NSCLC treated at Frankfurt University Hospital (FUH) following the availability of IO therapies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
